Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (257 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-07-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorescalationstagetherapystandard
  Phrases that lowered it: participantspharmacokineticsopenlabelevaluate the
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 9.2% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 888 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 149 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 8 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Design: sequential (lowers risk) · Design
• Minimum age: 0.5 (lowers risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors NCT02243917 · started 2014 · scored riskier than 42% of active trials terminated
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations NCT02124772 · started 2015 · scored riskier than 84% of active trials completed
• Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors NCT03245151 · started 2017 · scored riskier than 41% of active trials completed
• A Study of NB003 in Patients With Advanced Malignancies NCT04936178 · started 2021 · scored riskier than 28% of active trials completed
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 · started 2014 · scored riskier than 76% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.